| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-624
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6897
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6879
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2015-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2019-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-101971770-B1 |
| titleOfInvention |
Bi-specific antibodies and uses thereof |
| abstract |
Described herein are bispecific antibodies that specifically target tumor antigens of cancer cells to induce therapeutic agents into cancer cells, thereby thereby inhibiting the growth of the cancer and blocking the invasion or metastasis of cancer. The bispecific antibodies of the invention comprise a first antigen binding site that binds to polyethylene glycol (PEG); And a second antigen binding site that binds to a target ligand, such as a tumor antigen. |
| priorityDate |
2014-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |